Evaluating linaclotide for the treatment of irritable bowel syndrome with constipation in children and adolescents

INTRODUCTION Irritable bowel syndrome with constipation (IBS-C) is a common pediatric disorder of gut – brain interaction (DGBI) characterized by constipation-related bowel dysfunction and recurrent abdominal pain. Despite multimodal management, pharmacologic options specifically evaluated for pediatric IBS-C have historically been absent. Linaclotide, a guanylate cyclase-C agonist with local intestinal activity, has emerged as a mechanism-based therapy for this phenotype.AREAS COVERED This review summarizes the pharmacology, pharmacokinetics, clinical efficacy, safety, and regulatory status of linaclotide in pediatric IBS-C. Preclinical data support dual effects on intestinal secretion and visceral nociceptive signaling. Adult efficacy is supported by a mature clinical trial program showing consistent benefit across bowel and abdominal symptom endpoints. Pediatric evidence includes a published dose-ranging trial, real-world data, and a confirmatory regulatory trial that contributed to U.S. Food and Drug Administration (FDA) approval in patients aged 7 years and older.EXPERT OPINION Linaclotide represents an important addition to the pediatric IBS-C therapeutic landscape, particularly for children who remain symptomatic despite optimized conventional care. Its main conceptual advantage is addressing both bowel dysfunction and abdominal pain simultaneously. However, its role in practice will depend on full publication of confirmatory pediatric data, long-term safety experience, and access within multidisciplinary care pathways.